Stock Watch: The Complex Biologics Market Is…Complex
Lovenox And Copaxone Generic Challenges Foreshadow Biosimilar Market Inhibition
The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.
You may also be interested in...
With two recent divestments of biosimilar franchises and lackluster performances from smaller biosimilar biotechs, the sector needs some standard-bearing successes.
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?